Introduction
Individuals infected with the human immunodeficiency virus (HIV) can be affected by a wide variety of oral health problems. [1] [2] [3] [4] Many of these problems can progress to the point where the ravages of disease and, sometimes neglect, result in partial or complete loss of the natural dentition. [5] [6] [7] Severely compromised oral health has serious implications for the general health of patients with an HIV infection. Longterm maintenance of oral health becomes an important goal as significant advances in the management of this infectious disease become a reality. In particular, with the widespread use of potent antiretroviral regimens, referred to as highly active antiretroviral therapy (HAART), this treatment combination has increased the life expectancy for these individuals. [8] [9] [10] [11] Today, with the sustained reduction in AIDS-related morbidity and mortality, the prospect of living with HIV as a chronic, rather than, a terminal disease has never been greater.
Irrespective of HIV status, some patients who wear conventional mandibular complete dentures experience considerable difficulty adapting to their prostheses. There is increasing awareness two-implant, mandibular overdentures are superior to conventional dentures because this combined treatment offers better retention and support. 12, 13 Improved comfort, stability, function, and chewing efficiency with implant-supported overdentures have been documented. 13 Patients who receive two-implant, mandibular overdentures with opposing complete maxillary dentures report their quality of life is significantly higher than with conventional dentures. 12 With an increased survival rate, some HIV-infected edentulous patients who wear dentures are becoming informed consumers of oral healthcare and are requesting a variety of procedures, including dental implants.
There are a number of articles relating systemic factors as an important variable influencing the outcome of osseointegrated dental implants. Most of these articles arrive at this conclusion based on retrospective clinical studies or case reports. 14, 15 At present, it is unclear to the extent systemic factors interfere with the achievement of osseointegration and its maintenance over time. 16, 17 For this reason, there is considerable controversy as to whether such an oral surgical procedure should be performed on HIV-infected patients. 18 Except for occasional published case reports, [19] [20] [21] [22] there are no prospective studies in the English literature on the clinical outcome of endosseous dental implant procedures in HIV-positive patients. In 1998 Rajnay and Hochstetter 19 were the first to document the successful placement of an endosseous, root-form, single implant without complications in an HIV-infected adult. In a second case Baron and associates 20 described the complete rehabilitation of a 27-year-old HIVpositive female who was concurrently infected with Houston Committee for the Protection of Human Subjects (Protocol HSC-DB-99-005). Informed consent was obtained from each subject enrolled.
Subject Selection
Subjects selected to receive two osseointegrated dental implants were older than 18 21 reported the successful placement in an HIV-positive patient who was managed with eight dental implants; six in the maxilla and two in the mandible. Recently, Achong and associates 22 published the successful outcome, during a 24-month follow-up period, of dental implant placement in three HIV-infected patients. The first patient was a 56-year-old black male who received two implants and crowns. The second, a 45-year-old white male with a history of Hepatitis B infection, received two implants and crowns. The third was an edentulous 46-year-old male with a history of Hepatitis C who received two implants and a mandibular overdenture.
The results from these case reports are encouraging, but it is important to verify these isolated patient findings used prospective, controlled studies to determine the clinical success rate of dental implants in this group of immunocompromised patients. The purpose of this study was to evaluate and compare the shortterm outcome of osseointegrated dental implants, placed in the anterior mandible of edentulous HIV-positive and HIV-negative individuals, who required complete dentures.
Methods and Materials
This prospective, non-randomized, clinical trial evaluated the short-term success of osseointegrated implants in both HIV-positive and HIV-negative individuals. This study was conducted at Bering-Omega Dental Clinic (BODC) in Houston, TX, USA, a communitybased HIV-dedicated clinic for indigent adults and The University of Texas Dental Branch at Houston (UTDB). A standardized protocol was used for the preoperative evaluation, treatment planning, surgical placement, assessment of healing and osseointegration, as well as the prosthetic rehabilitation of implant-supported complete overdentures.
This research protocol was approved by The University of Texas Health Science Center at Lastly, any condition placing subjects at unacceptable health risk or if the individual was judged to be unlikely to comply with the study requirements disqualified them from participating in the study.
Examination Procedures
Besides an intraoral clinical examination, panoramic radiographs were obtained to screen for bony pathoses and to determine the amount of anterior mandibular bone present to facilitate the selection of the implant size to be used.
Treatment Procedures
Every participant received two endosseous dental implants (BioHorizons Implant System, Inc., Birmingham, AL, USA) to retain their mandibular overdentures, using appropriate attachments such as the standard O-ring attachment. After both dentures were fabricated, the mandibular denture was duplicated with clear acrylic (Vitacrylic ® Fricke International, Inc., Villa Park, IL, USA) to create the surgical drill guide.
For consistency, only two surgeons who followed the Brånemark surgical protocol 25, 26 placed all the implants in this study. All subjects were medicated with a broad-spectrum systemic antibiotic, primarily amoxicillin, one-hour prior to the surgery and up to seven days , postoperatively. 27 In addition, subjects rinsed with 0.12% chlorhexidine gluconate solution before surgery and twice a day for 15 days after surgery. Pain medication was prescribed, as needed.
Follow-up Care and Assessment
Subjects returned to the clinic for follow-up care and clinical assessment at regular intervals. When soft tissue healing was considered to be adequate, new dentures were inserted. The mandibular denture was relined in the anterior region, where the implants had been placed, with a soft relining material (CoeSoft, Dentsply International, Inc., York, PA, USA). On average, three months after the stage I surgery, the stage II surgery was performed. Two to three weeks following stage II surgery the implants were activated with the mandibular denture retained by O-ring attachments (BioHorizons Implant System, Inc., Birmingham, AL, USA).
Periapical radiographs were taken at the time of the loading to determine the alveolar bone level and to evaluate for any radiolucency surrounding the implants. Six months after the implants were loaded, periapical radiographs were taken to document changes in bone height and quality of surrounding bone. In addition, each implant was clinically evaluated for evidence of infection, pain, and mobility at the loading appointment and on the six-month follow-up visit.
The primary variable evaluated was the treatment outcome measured according to the guidelines for successful implants as established by Albrektsson and Zarb 14 with a single modifi cation. Both clinical and radiographic parameters were used to evaluate the success rate of the implants in both groups of subjects, and the criteria for success are briefl y described as follows: Since this was a six-month study, the vertical bone loss criterion was modifi ed to be less than 0.5 mm loss six months after implant loading, as opposed to less than 1.0 mm in the fi rst year and less than 0.2 mm annually, following the implant's fi rst year of service.
A lighted viewing table, a millimeter ruler, and 3-power magnifying glass were used to measure the vertical bone loss around each implant. On periapical radiographs taken at the time of implant loading, baseline bone measurements were made by a single examiner on the distal and mesial of each implant using the implant-abutment junction as a reference to the point where the bone contacts the body of the implant. 28 Each patient had two implants, and a total of four measurements were made. This procedure was repeated on radiographs of implants taken six months after implant loading. The differences in measurements between baseline and six months after loading, which represent marginal bone loss, were recorded.
Descriptive analysis of all the parameters measured in this study was conducted six months after activation to evaluate the osseointegration of the dental implants in each patient. Descriptive statistics including the mean, range, and percent success rate were used in this study for comparison between the control and test groups.
Results
A total of 29 subjects (17 males and 12 females) were enrolled in this study. A convenience sample of 20 subjects comprised the test group (HIVpositive), all of whom were treated at BODC. Of the 20 subjects in the test group, 15 (75%) completed the six-month protocol and five (25%) did not. Two subjects (10%) died from complications associated with their HIV infection and three (15%) dropped out of the study. A convenience sample of nine individuals comprised the control group (HIV-negative) and all subjects (100%) completed the protocol at UTDB. A summary of the demographic information of all the subjects enrolled in the test and control groups is presented in Table 1 . In general, the HIV-positive group was ethnically more diverse; had proportionally more male participants; and averaged 16 years younger than the test group. Besides HIV and antiretroviral treatment, the test Table 1 . Demographic summary of subjects in study.
group had a higher percentage of risk factors including an increased number of patients who were cigarette smokers and were diagnosed with diabetes.
Specific demographic information regarding the 20 subjects in the test group including the subjects' age, ethnicity, sex, use of tobacco products, history of diabetes, CD4 count, viral load, the use of HAART medications, and the treatment outcomes of the dental implants six months after loading is presented in Table 2 . Demographic information concerning the nine subjects in the control group is listed in Table 3 .
The treatment outcomes were assessed for each implant six months after loading. In this study all implants placed in subjects, who completed the six-month protocol, irrespective of their HIV status, had osseointegrated successfully (Tables  2 and 3 ). There was no evidence of infection, pain, bleeding, implant mobility, nor peri-implant radiolucency. All measurements of marginal bone loss for the test and the control groups were less than 0.5 mm. For both groups, the range was from 0.0 mm to 0.4 mm. The mean for the test group was 0.06 mm with a standard deviation of 0.09. For the control group, the mean was 0.18 with a standard deviation of 0.17. Both groups demonstrated a 100% short-term success rate. Figures 1-9 illustrate a clinical case of an HIV-positive patient, the corresponding radiographs at baseline (implant activation), and at the six-month follow-up appointment.
Various healing responses, following stage I and after stage II surgery, requiring minor corrective measures were encountered during the course of this study. These are presented in Table 4 for the test group and in Table 5 for the control group. Also, summarized in these tables are the corrective measures taken when indicated.
In the test group six subjects (30%) experienced at least one healing response which required corrective intervention. The most frequently encountered healing response requiring intervention was soft tissue overgrowth around the implants in three (15%) of the subjects (T1, T3, and T7). Four subjects (20%) experienced other noteworthy considerations including the activation of recurrent intraoral herpes simplex infection on the hard palate (T1), porous Misch Bone Density Classification D4 24 (T5), compromised alignment of the implants due to the anatomy of the anterior mandible (T12), and the lack of keratinized tissue around the implants (T20). In the control group two subjects (22.2%) had corrective measures taken; one (11.1%) required removal of soft tissue overgrowth around an implant (C9), the other (11.1%) had excess bone growth over the implant which required osseous recontouring (C4). 
Discussion
Based on the short-term results, both HIV-positive and HIV-negative individuals demonstrated clinical and radiographic success following placement of dental implants for the retention of a mandibular denture. Irrespective of the HIV status, the high success rate could be explained in part by the site of placement of the dental implants. Mandibular anterior dental implants are known to have the most favorable outcome due to the ideal anatomical structure and bone type found in that region. 25, 29, 30 All post-surgical corrective measures following stage I and after stage II surgery were resolved successfully and the implants functioned well. The most common corrective treatment was the removal of the soft tissue overgrowth adjacent to the implants. This tissue response was found in both the test group (15%) and in the control group (11%). The corrective treatment for these cases included either CO 2 laser ablation or removal of the excess tissues with a scalpel. The soft tissues were allowed to heal completely before the implants were activated. Healing was uneventful after the redundant alveolar mucosa was excised for both groups.
It should be pointed out five subjects in the test group (25%), T16, T17, T18, T19, and T20, had CD4 counts slightly above or less than 200 cell/mm 3 and were classified as having AIDS. In addition, one of these five, T18, was also a controlled type II diabetic and smoked at least one pack of cigarettes a day. A total of four subjects in the test group (20%), T4, T9, T15, and T18, had controlled type II diabetes. Three of these subjects who completed the study had successful osseointegration of their dental implants. In this study HIV-infected individuals who have AIDS and/or have well-controlled type II diabetes underwent successful dental implant therapy despite these significant risk factors.
Little information has been published concerning post-insertion complications encountered with complete dentures in patients who are HIVpositive. 5, 31 With regard to oral complications during prosthetic treatment for edentulous non-HIV-infected patients, there are reports describing problems associated with xerostomia [32] [33] [34] and candidiasis. [35] [36] [37] It should be noted these are two complications frequently associated with HIV infection, but in the present study these conditions did not affect the short-term prognosis of dental implants.
Some clinicians do not recommend the placement of dental implants in HIV-positive patients because of a perceived risk of developing complications from invasive dental treatment. While it is generally accepted a disturbance of the immune function in a patient may lead to poor wound healing and infection, there is considerable controversy regarding the incidence of delayed wound healing and other post-extraction complications in HIV-infected patients. Of clinical importance, studies evaluating the extraction of teeth in HIV-infected patients have demonstrated there is not a statistically significant increased risk for post-extraction complications when compared with non-HIV-infected patients. [38] [39] [40] A recent systematic review of the literature by Patton and associates 41 concluded the evidence is insufficient to determine if there is a higher risk for developing complications following invasive oral surgical procedures in this immunocompromised group of patients. Although the number of patients in this study is limited, the findings illustrated the surgical procedure of placing dental implants is also well tolerated in HIV-infected individuals.
Cigarette smoking is generally considered to be a significant risk factor in the prognosis of dental implants. After studying the association between the failure of dental implants and cigarette smoking, Bain and Moy 42 suggested the patient cease smoking at least one week prior to surgery to allow reversal of higher levels of platelet adhesion and blood viscosity as well as the shorter-term effects associated with nicotine.
These authors recommended patients should avoid tobacco for at least two months after implant placement. By that time bony healing should have progressed to the osteoblastic phase and early osseointegration should be established. 43, 44 Lambert and associates 45 reported smoking does not contribute to early implant failures between the time of implant placement and its uncovering. However, greater failures seem to appear between the time following uncovering and before the insertion of the prosthesis. Their results suggest implant failures in smokers are not the result of poor healing or osseointegration but rather of exposure of peri-implant tissues to the insult from tobacco smoke. They also suggest the detrimental effects may be reduced by cessation of smoking, use of preoperative antibiotics, and use of hydroxyapatite-coated implants.
It is very interesting to note of the 15 subjects in the test group who completed the study, 11 subjects (73%) smoked at least a pack of cigarettes a day. Only one subject in the control group (11%) was a smoker. Despite the high incidence of tobacco use in the HIV-infected group, all of the cigarette smokers who completed the study achieved successful osseointegration of their dental implants. In this study patients who smoked were asked to discontinue the habit for at least three weeks after the surgery. All of these patients claimed to have been compliant with the smoking cessation instructions which probably reduced the deleterious effects of smoking on dental implant health and increased the probability for a favorable, short-term outcome. [42] [43] [44] [45] [46] When a patient has a chronic disease, such as HIV infection, hospitalizations, increased risk for opportunistic infections, and rigorous medication dosing schedules may affect patient compliance and motivation. Clinicians need to be aware of the various complications that may occur during treatment. Patients may become ill and require hospitalization which may interrupt the ideal timing and sequence of dental treatment. In this study two subjects, T10 and T14, died from complications of the HIV disease, despite adhering to a well defined list of exclusion criteria. Typically, patients must be able to tolerate several long appointments, endure oral discomfort and surgical procedures, and demonstrate a willingness to adhere to home care instructions and a maintenance schedule. For a variety of medical, socioeconomic, and psychological reasons, HIV-infected individuals may not be able to adhere to the treatment protocol and may not complete their dental care. In this study three subjects (T3, T4, and T16) dropped out of the study prematurely, and their reasons for discontinuing ranged from hospitalizations, relocations to another state, and incarceration.
When properly prescribed and performed, endosseous implant therapy can greatly improve the masticatory and phonetic function of the prosthesis. Regardless of HIV status, dental implant therapy can restore appearance and function, improve nutrition, and enhance the quality of life. Clinicians need scientific evidence to justify the provision of implant dentistry to patients who are HIV-infected. In addition, if invasive surgical procedures are performed on this special group of patients, it is important for the clinician to understand the common manifestations and complications of this disease, including any systemic therapies that may impact treatment outcome. As the number of immunocompromised patients who could benefit from osseointegrated implants continues to increase, the dental profession will need to address all the treatment options available to this group of medically complex patients.
Conclusion
This is the first prospective study of the placement of dental implants in HIV-positive individuals. After a six-month evaluation, all dental implants were defined as being successfully integrated regardless of the HIV status of the individual. No differences were found between the HIV-infected and uninfected groups regarding the clinical response and integration of endosseous dental implants, as measured by standardized parameters.
This short-term study demonstrated osseointegrated dental implants are well tolerated and are a predictable treatment option for the immunocompromised patient. Extended followup of the subjects who participated in this study is desirable in order to determine the long-term prognosis of dental implants in the HIV-infected individual.
